Determining molecular predictors of adverse drug reactions with causality analysis based on structure learning

Journal of the American Medical Informatics Association

Volumn 21, Issue 2, 2014, Pages 245-251

  Liu, Mei ^a   Cai, Ruichu ^b   Hu, Yong ^c   Matheny, Michael E ^d,e   Sun, Jingchun ^f   Hu, Jun ^g   Xu, Hua ^f  

^a University Heights   (United States)

^b GUANGDONG UNIVERSITY OF TECHNOLOGY   (China)

^c GUANGDONG UNIVERSITY OF FOREIGN STUDIES   (China)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF TEXAS   (United States)

^g SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHMS; ARTIFICIAL INTELLIGENCE; BAYES THEOREM; CAUSALITY; DATABASES, GENETIC; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; LOGISTIC MODELS; MOLECULAR STRUCTURE; STATISTICS, NONPARAMETRIC; SUPPORT VECTOR MACHINES;

EID: 84894087399     PISSN: 10675027     EISSN: 1527974X     Source Type: Journal    
DOI: 10.1136/amiajnl-2013-002051     Document Type: Article

References (67)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200-5.
2. Jha AK, Kuperman GJ, Rittenberg E, et al. Identifying hospital admissions due to adverse drug events using a computer-based monitor. Pharmacoepidemiol Drug Saf 2001;10:113-19.
3. Daly AK. Pharmacogenomics of adverse drug reactions. Genome Med 2013;5:5.
4. Ingelman-Sundberg M. Pharmacogenomic biomarkers for prediction of severe adverse drug reactions. N Engl J Med 2008;358:637-9.
5. Roden DM, Altman RB, Benowitz NL, et al. Pharmacogenomics: challenges and opportunities. Ann Intern Med 2006;145:749-57.
6. Wilke RA, Lin DW, Roden DM, et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov 2007;6:904-16.
7. Pauwels E, Stoven V, Yamanishi Y. Predicting drug side-effect profiles: a chemical fragment-based approach. BMC Bioinformatics 2011;12:169.
8. Woosley RL, Cossman J. Drug development and the FDA's Critical Path Initiative. Clin Pharmacol Ther 2007;81:129-33.
9. Pouliot Y, Chiang AP, Butte AJ. Predicting adverse drug reactions using publicly available PubChem BioAssay data. Clin Pharmacol Ther 2011;90:90-9.
10. Chiang AP, Butte AJ. Data-driven methods to discover molecular determinants of serious adverse drug events. Clin Pharmacol Ther 2009;85:259-68.
11. Kalisch M, Buhlmann P. Estimating high-dimensional direced acyclic graphs with the PC-algorithm. J Mac Learn Res 2007;8:613-36.
12. Cai R, Zhang Z, Hao Z. BASSUM: a Bayesian semi-supervised method for classification feature selection. Pattern Recognit 2011;44:811-20.
13. Evans WE, Johnson JA. Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet 2001;2:9-39.
14. Pirmohamed M, Park BK. Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci 2001;22:298-305.
15. Williams JA, Hyland R, Jones BC, et al. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 2004;32:1201-8.
16. Sharma SK, Balamurugan A, Saha PK, et al. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 2002;166:916-19.
17. Cooper GM, Johnson JA, Langaee TY, et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 2008;112:1022-7.
18. O'Donohue J, Oien KA, Donaldson P, et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 2000;47:717-20.
19. Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 2008;359:789-99.
20. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002;287:1690-8.
21. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000;356:1667-71.
22. Fliri AF, Loging WT, Thadeio PF, et al. Analysis of drug-induced effect patterns to link structure and side effects of medicines. Nat Chem Biol 2005;1:389-97.
23. Campillos M, Kuhn M, Gavin AC, et al. Drug target identification using side-effect similarity. Science 2008;321:263-6.
24. Scheiber J, Chen B, Milik M, et al. Gaining insight into off-target mediated effects of drug candidates with a comprehensive systems chemical biology analysis. J Chem Inf Model 2009;49:308-17.
25. Fuzuzaki M, Seki M, Kashima H, et al. Side effect prediction using cooperative pathways. IEEE International Conference on Bioinformatics and Biomedicine; Washington DC; 2009:142-7.
26. Xie L, Li J, Bourne PE. Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP inhibitors. PLoS Comput Biol 2009;5:e1000387.
27. Brouwers L, Iskar M, Zeller G, et al. Network neighbors of drug targets contribute to drug side-effect similarity. PLoS ONE 2011;6:e22187.
28. Wang Y, Bolton E, Dracheva S, et al. An overview of the PubChem BioAssay resource. Nucleic Acids Res 2010;38(Database issue):D255-66.
29. Lounkine E, Keiser MJ, Whitebread S, et al. Large-scale prediction and testing of drug activity on side-effect targets. Nature 2012;486:361-7.
30. Bender A, Scheiber J, Glick M, et al. Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure. ChemMedChem 2007;2:861-73.
31. Scheiber J, Jenkins JL, Sukuru SC, et al. Mapping adverse drug reactions in chemical space. J Med Chem 2009;52:3103-7.
32. Hammann F, Gutmann H, Vogt N, et al. Prediction of adverse drug reactions using decision tree modeling. Clin Pharmacol Ther 2010;88:52-9.
33. Yamanishi Y, Kotera M, Kanehisa M, et al. Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework. Bioinformatics 2010;26:i246-54.
34. Cami A, Arnold A, Manzi S, et al. Predicting adverse drug events using pharmacological network models. Sci Transl Med 2011;3:114ra27.
35. Liu M, Wu Y, Chen Y, et al. Large-scale prediction of adverse drug reactions using chemical, biological, and phenotypic properties of drugs. J Am Med Inform Assoc 2012;19(e1):e28-35.
36. Vilar S, Harpaz R, Chase HS, et al. Facilitating adverse drug event detection in pharmacovigilance databases using molecular structure similarity: application to rhabdomyolysis. J Am Med Inform Assoc 2011;18(Suppl 1):i73-80.
37. Vilar S, Harpaz R, Santana L, et al. Enhancing adverse drug event detection in electronic health records using molecular structure similarity: application to pancreatitis. PLoS ONE 2012;7:e41471.
38. Mukhopadhyay ND, Chatterjee S. Causality and pathway search in microarray time series experiment. Bioinformatics 2007;23:442-9.
39. Kim YA, Wuchty S, Przytycka TM. Identifying causal genes and dysregulated pathways in complex diseases. PLoS Comput Biol 2011;7:e1001095.
40. Schadt EE, Lamb J, Yang X, et al. An integrative genomics approach to infer causal associations between gene expression and disease. Nat Genet 2005;37:710-17.
41. Cai R, Zhang Z, Hao Z. Causal gene identification using combinatorial V-structure search. Neural Networks 2013; 43:63-71
42. Mani S, Cooper GF. Causal discovery from medical textual data. Proceedings/AMIA Annual Symposium AMIA Symposium. 2000:542-6.
43. Hu Y, Zhang X, Ngai EWT, et al. Software project risk analysis using Bayesian networks with causality constraints. Decis Support Syst 2013;56:439-49.
44. Kuhn M, Campillos M, Letunic I, et al. A side effect resource to capture phenotypic effects of drugs. Mol Syst Biol 2010;6:343.
45. Bodenreider O. The Unified Medical Language System (UMLS): integrating biomedical terminology. Nucleic Acids Res 2004;32(Database issue):D267-70.
46. Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Safety 1999;20:109-17.
47. Chen B, Wild D, Guha R. PubChem as a source of polypharmacology. J Chem Inf Model 2009;49:2044-55.
48. Bolton E, Wang Y, Thiessen PA, et al. PubChem: integrated platform of small molecules and biological activities. Chapter 12 in Annual Reports in Computational Chemistry. Washington, DC: American Chemical Society, 2008.
49. Knox C, Law V, Jewison T, et al. DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res 2010;39(Database issue):D1035-41.
50. Wishart DS, Knox C, Guo AC, et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 2008;36(Database issue):D901-6.
51. Wishart DS, Knox C, Guo AC, et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 2006;34(Database issue): D668-72.
52. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 2000;28:27-30.
53. Kanehisa M, Goto S, Furumichi M, et al. KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res 2010;38 (Database issue):D355-60.
54. Kanehisa M, Goto S, Hattori M, et al. From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res 2006;34(Database issue):D354-7.
55. Pearl J, Verma TS. A theory of inferred causation. Proceedings of the 2nd International Conference on Principles of Knowledge Representation and Reasoning; April 1991; Cambridge, Massachusetts, 1991:441-52.
56. Spirtes P, Glymour C, Scheines R. Causation, prediction, and search. 2nd edn. The MIT Press, 2001.
57. Friedman JH, Hastie T, Tibshirani R. RegularizationPaths for generalized linear models via coordinate descent. J Stat Software 2010;33:1-22.
58. Online Mendelian Inheritance in Man, OMIM. http://omim.org/
59. Birnbaum ZW, Tingey FH. One-sided confidence contours for probability distribution functions. Ann Math Stat 1951;22:592-6.
60. Conover WJ. Practical nonparametric statistics. New York: John Wiley & Sons, 1971.
61. Chang C C, Lin C J. LIBSVM: a library for support vector machines. ACM Trans Intell Syst Technol 2011;2:1-27.
62. Hadzic N, Bull LN, Clayton PT, et al. Diagnosis in bile acid-CoA: amino acid N-acyltransferase deficiency. World J Gastroenterol 2012;18:3322-6.
63. Price T, Aitken J, Simpson ER. Relative expression of aromatase cytochrome P450 in human fetal tissues as determined by competitive polymerase chain reaction amplification. J Clin Endocrinol Metab 1992;74:879-83.
64. Grohe C, Kahlert S, Lobbert K, et al. Expression of oestrogen receptor alpha and beta in rat heart: role of local oestrogen synthesis. J Endocrinol 1998;156:R1-7.
65. Bell JR, Mellor KM, Wollermann AC, et al. Aromatase deficiency confers paradoxical postischemic cardioprotection. Endocrinology 2011;152:4937-47.
66. Stang PE, Ryan PB, Racoosin JA, et al. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med 2010;153:600-6.
67. Coloma PM, Schuemie MJ, Trifiro G, et al. Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. Pharmacoepidemiol Drug Saf 2011;20:1-11.